Sight Sciences, Inc. Stock Price, News & Analysis

Sight Sciences, Inc. (Nasdaq: SGHT) successfully defeated all four patent invalidity challenges from Alcon and Ivantis regarding its Hydrus® Microstent technology. The U.S. Patent Office denied the petitions, confirming the validity of Sight Sciences’ patents. This decision follows a lawsuit filed in 2021, seeking damages and injunctive relief against Ivantis for patent infringement. A jury trial is set for April 8, 2024, in Wilmington, Delaware. Sight Sciences boasts a robust patent portfolio covering innovative approaches to glaucoma treatment and aims to vigorously defend its intellectual property.

Sight Sciences, Inc. (Nasdaq: SGHT) reported strong financial results for Q4 and full-year 2022, with total revenue of $71.3 million, a 46% increase year-over-year. Q4 revenue reached $20.5 million, up 40% compared to Q4 2021. Surgical Glaucoma revenue rose to $18.8 million and Dry Eye revenue surged by 135% to $1.8 million. Operating expenses decreased sequentially to $33.9 million from Q3 2022. However, the net loss for Q4 was $16.9 million, while total operating expenses for 2022 increased by 56% year-over-year to $142.9 million. The company projects 2023 revenue between $89 million and $94 million, indicating expected growth of 25% to 32%.

Sight Sciences (Nasdaq: SGHT) has officially launched the Ergo-Series of the OMNI® Surgical System in the U.S., aimed at enhancing minimally invasive, implant-free glaucoma procedures.

The new features include:

• Improved Handle Ergonomics: Enhances precise control for surgeons.
• Simplified Viscoelastic Preparation: Removable luer connector for better clearance during surgery.
• New Cannula Tip Design: Enables gentler access to Schlemm's canal.

The Ergo-Series maintains the same therapeutic functionality as previous models, enabling effective treatment for patients with primary open-angle glaucoma.

Sight Sciences, Inc. (Nasdaq: SGHT) will report its financial results for the fourth quarter and full year ending December 31, 2022, on March 13, 2023, after market close. The management will discuss the results in a conference call at 1:30 PM PT / 4:30 PM ET. Investors can listen live or access a replay on the company's website for at least 90 days. Sight Sciences focuses on innovative eye care solutions, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These products aim to improve patient outcomes through minimally invasive techniques, addressing significant health issues in eye care.

Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology firm, announced its participation in the Citi 2023 Healthcare Services, Medtech, Tools & HCIT Conference in New York on March 1, 2023, at 3:30 PM ET. The company will host a fireside chat, which will be accessible live and archived on its website’s 'Investors' section. Sight Sciences focuses on innovative, minimally invasive solutions for prevalent eye diseases, including the OMNI® Surgical System for glaucoma and the TearCare® System for dry eye disease. These advancements aim to enhance patient care and replace outdated treatment methods.

Sight Sciences announced that over 1,000 eye care practices have integrated its TearCare® System, aimed at treating dry eye disease due to meibomian gland dysfunction (MGD). This FDA-cleared system provides localized heat therapy in conjunction with manual gland expression. Since its launch in 2019, the system has gained traction among practitioners, supported by favorable clinical trial results, including the ongoing SAHARA study designed to compare its efficacy with traditional treatments. The 1,000th installation was at Total Eye Care in Long Island, reflecting a growing acceptance and confidence in the TearCare® System.

Sight Sciences (Nasdaq: SGHT) announced preliminary financial results for Q4 and full year 2022, highlighting a projected 40% increase in Q4 revenue, estimated between $20.4 million and $20.6 million. Full year revenue is expected to be $71.2 million to $71.4 million, marking a 46% year-over-year growth. Surgical Glaucoma and Dry Eye product revenues showed significant growth, with Dry Eye revenues increasing by 134% compared to the prior year. Additionally, the company announced a CFO transition, with interim leadership stepping in as the search for a replacement begins.

Verana Health and Sight Sciences have initiated a research collaboration to enhance treatment outcomes for patients with primary open-angle glaucoma (POAG). This partnership will utilize Verana's Qdata Glaucoma real-world data module, which encompasses over 341,000 MIGS records from more than 5 million patients with extensive follow-up data. The OMNI Surgical System, a minimally invasive solution for lowering intraocular pressure, will be evaluated for its long-term efficacy and safety. POAG currently affects 2.7 million Americans, making this research crucial.

Sight Sciences, Inc. (Nasdaq: SGHT) presented data at the 2022 American Academy of Optometry showing significant improvements in meibomian gland function and dry eye symptoms using the TearCare® System. A study of 78 patients indicated a 63% improvement in gland function and a 44% reduction in dry eye symptoms over 12 months. Results demonstrated sustained efficacy, with symptom relief lasting up to 18 months post-treatment. The findings suggest potential for broader adoption of TearCare® in treating meibomian gland disease, addressing patient compliance with traditional eye drop regimens.